Andere Sprachen CytoMed Therapeutics Limited

Aktien

A3D4GB

SGXZ17669631

GDTC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 26.06.2024			% 5 Tage	% 1. Jan.
2,03 ^USD	-0,47 %		+5,75 %	-58,56 %

24.05.	CytoMed Therapeutics Limited genehmigt den Rücktritt von Wu Tao Thomas und Dr. Lucas Luk Tien Wee als Direktoren	CI
22.04.	CytoMed Therapeutics Limited berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

CytoMed Therapeutics : Board re organization Form 6 K	20.06.
CytoMed Therapeutics : Annual Shareholders Meeting - Form 6-K	24.05.
CytoMed Therapeutics Limited Announces Board and Audit Committee Changes	24.05.
CytoMed Therapeutics : PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	24.04.
CytoMed Therapeutics Limited Reports Earnings Results for the Full Year Ended December 31, 2023	22.04.
Certain Ordinary Shares of CytoMed Therapeutics Limited are subject to a Lock-Up Agreement Ending on 14-APR-2024.	14.04.
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18.03.
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18.03.
CytoMed Therapeutics Limited to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies	18.03.
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04.03.
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04.03.
CytoMed Therapeutics Limited Announces Research Collaboration with Sengkang General Hospital Pte Ltd to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair	04.03.
CytoMed Therapeutics Receives Patent in Malaysia for its Prospective Cancer Therapy	29.01.
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology	29.01.
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology	29.01.
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology	05.12.
CytoMed Therapeutics Limited Reports Earnings Results for the Half Year Ended June 30, 2023	17.11.
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update	17.11.
CytoMed Therapeutics to Present at the Benchmark Company s Upcoming Discovery One-on-One Investor Conference	15.11.
CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CytoMed Therapeutics Limited

Aktien

A3D4GB

SGXZ17669631

GDTC

Andere Sprachen

Filter